Thus, hepatic Sam68 potentiates CREB/CRTC2-mediated glucose production, contributes to the pathogenesis of insulin resistance, and may serve as a therapeutic target for T2D. The gene discussed is CREB1; the disease is type 2 diabetes mellitus.